In Brief: Genzyme
This article was originally published in The Gray Sheet
Executive Summary
Genzyme: Proposes a buyout of minority interest in Integrated Genetics Laboratories following a Feb. 10 announcement by a committee of IG directors that "various strategic alternatives" are being considered. Genzyme currently owns about 69% of the firm's outstanding shares. The proposal would give public stockholders of IG .12368 shares of Genzyme General Division Common Stock for each IG share. Genzyme estimates the total transaction to be valued at $14 mil...